Cagrilintide: Preclinical Research Overview
Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.
The Obesity Challenge
Obesity is one of today’s most urgent public-health problems. In the United States, roughly 42% of adults meet criteria for obesity—a prevalence that has nearly tripled in five decades. Globally, more than 650 million people are affected. The consequences are profound: higher risks of cardiovascular disease, type 2 diabetes, stroke, certain cancers, and reduced quality and length of life.
Importantly, obesity is not the simple result of “willpower.” It reflects a complex interplay among genetics, hormones, metabolism, environment, and behavior—amid abundant, calorie-dense food and increasingly sedentary routines. These factors make weight loss hard to achieve and even harder to sustain. Relapse after dieting is common, and many approved medications target only narrow pathways (e.g., appetite alone), often with tolerability limits or modest efficacy.
Why Cagrilintide Is of Interest
Cagrilintide, a long-acting analogue of the hormone amylin, takes a multi-mechanistic approach and is studied alongside other research peptides that act through complementary circuits, such as GLP-1 receptor agonists.
Amylin, Briefly
Amylin is co-secreted with insulin following meals. It slows gastric emptying, suppresses postprandial glucagon, and signals fullness to the brain—supporting glucose regulation and appetite control. Beyond metabolism, amylin influences bone turnover and vascular tone, but its therapeutic use has been limited by rapid degradation in the body.
What Cagrilintide Does
Cagrilintide mimics amylin’s actions with far greater stability and a longer half-life. It acts on central satiety pathways, notably in the hypothalamus, and delays gastric emptying.
Clinical Development and Emerging Use Cases
Cagrilintide is under active study for overweight and obesity. Investigators are also exploring fixed-dose combinations with agents such as semaglutide to leverage distinct mechanisms across the appetite–energy balance axis.
Representative Evidence (Research Only)
Amylin + Leptin in Diet-Induced Obesity (Preclinical)
In diet-induced obese rats, combined amylin and leptin produced synergistic weight loss during induction and best maintained reductions during continuation therapy. Rats maintained on amylin + leptin preserved weight loss and favorable body-composition and metabolic changes, whereas placebo or leptin alone led to weight regain. These data support exploring multi-hormonal strategies that address complementary nodes in energy homeostasis.
Product available for research use only:
References
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Lau, David C W et al. The Lancet, Volume 398, Issue 10317, 2160 – 2172
- Gadde KM, Allison DB. Long-acting amylin analogue for weight reduction. Lancet. 2021 Dec 11;398(10317):2132-2134. doi: 10.1016/S0140-6736(21)01999-1. Epub 2021 Nov 16. PMID: 34798059.
- Mathiesen DS, Bagger JI, Knop FK. Long-acting amylin analogues for the management of obesity. Curr Opin Endocrinol Diabetes Obes. 2022 Apr 1;29(2):183-190. doi: 10.1097/MED.0000000000000716. PMID: 35066542.
- Trevaskis JL, Lei C, Koda JE, Weyer C, Parkes DG, Roth JD. Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats. Obesity (Silver Spring). 2010 Jan;18(1):21-6. doi: 10.1038/oby.2009.187. Epub 2009 Jun 18. PMID: 19543217.
